Daiichi Sankyo Europe Gmbh
SpainAll drugs from this manufacturer
-
It is used to treat adults with HER2-positive breast cancer (metastatic or unresectable), breast cancer with low or very low HER2 expression, non-small cell lung cancer with an HER2 mutation, and HER2-positive stomach cancer.
Dosage form: powder for concentrate for solution for infusion
Active substance Dosage trastuzumab deruxtecan 107 mg -
It is used in adults to prevent the formation of blood clots in the brain and other blood vessels in people with a type of irregular heartbeat (non-valvular atrial fibrillation) and other risk factors. It is also used to treat blood clots in the veins of the legs (deep vein thrombosis) and in the lungs (pulmonary embolism), helping to prevent their recurrence.
Dosage form: tablets, film-coated
Active substance Dosage edoxaban tosylate 20,205 mg -
It is used in adults to prevent the formation of blood clots in the brain and other blood vessels in people with an irregular heart rhythm (non-valvular atrial fibrillation) and other risk factors. It is also used to treat blood clots in the veins of the legs (deep vein thrombosis) and in the lungs (pulmonary embolism), and to prevent them from recurring.
Dosage form: tablets, film-coated
Active substance Dosage edoxaban tosylate 40,410 mg -
It is used in adults to prevent the formation of blood clots in the brain and other blood vessels in people with an irregular heartbeat called non-valvular atrial fibrillation. It is also used to treat blood clots in the leg veins (deep vein thrombosis) and in the lungs (pulmonary embolism), as well as to prevent them from recurring.
Dosage form: tablets, film-coated
Active substance Dosage edoxaban tosylate 40,410 mg -
It is used in adults to prevent the formation of blood clots in the brain (stroke) and other blood vessels in people with a type of irregular heartbeat called non-valvular atrial fibrillation and other risk factors. It is also used to treat blood clots in the veins of the legs (deep vein thrombosis) and in the lungs (pulmonary embolism), and to prevent their recurrence.
Dosage form: tablets, film-coated
Active substance Dosage edoxaban tosylate 80,820 mg -
It is used in adults to prevent the formation of blood clots in the brain (stroke) and other blood vessels in people with an irregular heart rhythm called non-valvular atrial fibrillation. It is also used to treat blood clots in the veins of the legs (deep vein thrombosis) and in the lungs (pulmonary embolism), and to prevent them from occurring again.
Dosage form: tablets, film-coated
Active substance Dosage edoxaban tosylate 80,820 mg -
It is used to reduce 'bad' cholesterol (LDL cholesterol) levels in the blood in adults with primary hypercholesterolemia or mixed dyslipidemia, or in adults with elevated cholesterol levels who already have cardiovascular disease or are at risk of cardiovascular events. It is used when statins are insufficient or cannot be used.
Dosage form: tablets, film-coated
Active substance Dosage bempedoic acid 180 mg -
It is used to reduce 'bad' cholesterol (LDL cholesterol) levels in the blood in adults with primary hypercholesterolemia, mixed dyslipidemia, or individuals with cardiovascular risk. It is also used when other treatments, such as statins or ezetimibe alone, have not been sufficient.
Dosage form: tablets, film-coated
Active substance Dosage bempedoic acid 180 mg ezetimibe 10 mg -
It is used in combination with chemotherapy to treat adults with acute myeloid leukemia (AML) who have a specific mutation called FLT3-ITD. It may also be used after a bone marrow transplant once the patient has recovered sufficiently.
Dosage form: tablets, film-coated
Active substance Dosage quizartinib dihydrochloride 17,7 mg -
It is used in combination with chemotherapy to treat adults with acute myeloid leukemia (AML) who have a specific mutation called FLT3-ITD. It may also be used after a bone marrow transplant once the patient has recovered sufficiently.
Dosage form: tablets, film-coated
Active substance Dosage quizartinib dihydrochloride 26,5 mg